Introduction {#sec1}
============

Bone--tendon junction (BTJ) is a unique structure linking tendon and bone. It consists of three district tissues: bone, tendon, and a special tissue, known as fibrocartilage that plays a major role in minimizing stress and strain from bone to tendon \[[@bib1],[@bib2]\]. BTJ injuries are common in sports, such as tears or ruptures of anterior cruciate ligament (ACL) or rotator cuff and injuries of patellar--patellar tendon, but the healing or reconstruction of BTJ is very difficult to achieve clinically because of the formation of fibrous scar tissue after BTJ injuries \[[@bib3],[@bib4]\]. For instance, it was reported that the failure rates range 20%--94% in rotator cuff repair \[[@bib5],[@bib6]\] and 10%--25% in ACL reconstruction \[[@bib7]\].

The mechanism of fibrocartilage regeneration is not well known. Like chondrocytes, the fibrocartilage-like cells are generally round or oval in shape, with typical features of chondrocytes such as the expression of collagen II/X. In addition, they also exhibit certain fibroblastic phenotypes, such as the expression of collagen I \[[@bib1]\], which was also evident in TSPCs but not in bone mesenchymal stem cells (BMSCs) \[[@bib8]\]. Perez Castro et al. \[[@bib9]\] found that at least 25% of the cells in fibrocartilage express collagen I and II. The difference between fibrocartilage and cartilage cells are likely attributed to the differential expression of collagen subtypes \[[@bib10]\].

The role of BMSCs in fibrocartilage formation at BTJ has been reported \[[@bib11]\]. BMSCs was able to differentiate to fibrocartilage-like cells *in vivo* and *in vitro* \[[@bib12],[@bib13]\]. Interestingly, it is also evident that bone--tendon junction healing was facilitated by TSPCs transplanted in nude mice \[[@bib14]\]. Consistently, fibrocartilage-like tissue was detected in TSPCs-transplanted nude rats \[[@bib15]\]. Lui et al. \[[@bib16]\] also reported that tendon stem cells sheet could enhance bone--tendon junction healing with more Sharpey\'s fibres, which have characteristics of fibrocartilage at BTJ.

It has been documented that TSPCs contain a population of mesenchymal progenitors that have multidifferentiation potential \[[@bib14],[@bib15],[@bib17]\]. TSPCs derived from rat, mouse, rabbit, and human tendon tissue could differentiate towards osteoblasts, adipocytes, and chondrocytes *in vitro* \[[@bib14],[@bib15],[@bib17]\]. TSPCs have some unique features which are different from BMSCs, including the expression of fibroblastic marker collagen I \[[@bib8]\] and tenogenic markers, tenascin C, and tenomodulin \[[@bib14]\]. The effect of TSPCs on tendon repair were previously documented \[[@bib18],[@bib19]\]; however, their potential role in fibrochondrogenic differentiation has not been well studied.

In this study, we examined the potential of TSPCs to differentiate to fibrocartilage-like cells under differentiating conditions both *in vitro* and *in vivo*. Our data indicate that TSPCs are able to differentiate to fibrochondrocyte-like cells, and the fibrochondrogenic characteristics were conserved even *in vivo* and therefore might have potential application for fibrocartilage regeneration in the repair of BTJ.

Materials and methods {#sec2}
=====================

Isolation of tendon-derived stem/progenitor cells (TSPCs) from patellar tendon {#sec2.1}
------------------------------------------------------------------------------

We obtained TSPCs from human patellar tendon samples of four patients (n ​= ​4) who underwent ACL reconstruction using bone--patellar tendon--bone autografts with patients\' consent. The age range of patients was from 22 to 32 years. TSPCs were isolated from the patellar tendon tissues \[[@bib17]\]. First, 0.25% of trypsin was used to predigest the tendon for 15 ​min, and these tissues were cut into small pieces. Second, 3 ​mg/ml of collagenase I (Sigma[-]{.ul}Aldrich, St. Louis, MO) in plain low glucose Dulbecco\'s modified Eagle\'s medium (LG-DMEM) (Gibco, Invitrogen, Carlsbad, CA) was used to digest these small pieces for at least 2 ​h at 37 ​°C, and then this digestion solution was passed through a cell strainer (70 ​μm) (Becton Dickinson, Franklin Lakes, NJ) to obtain a uniform single-cell suspension. After centrifugation and washing, the cells were resuspended in LG-DMEM supplemented with 10% foetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). The cells were plated at three different cell density (50, 100, and 200 ​cells/cm^2^) and cultured in LG-DMEM containing with 10% FBS at 5% CO~2~, 37 ​°C for 12 days. Cell colonies formed from the isolated tendon cells were either subcultured for next experiments or stained with 0.5% crystal violet (Sigma-Aldrich) after being fixed with 70% ethanol. The number of colonies formed were counted. All the next experiments were performed with Passage 3--5 of human TSPCs.

Fluorescence-activated cell sorting (FACS) analysis of human TSPCs {#sec2.2}
------------------------------------------------------------------

10^5^ TSPCs at Passage 3 were harvested to detect markers of stem cells, including cell surface markers (CD29 and CD105), monocytic and neutrophil markers (CD14), mesenchymal stem cell marker (CD44), leucocyte marker (CD45), and fibroblastic marker (CD90) using the flow cytometry analyses. TPSCs were incubated in 1 ​× ​phosphate-buffered saline (PBS) with antibodies afforementioned so that cells could be immunolabeled with 1 ​μg of phycoerythrin (PE)- or fluorescein isothiocyanate (FITC)-conjugated mouse antihuman monoclonal antibodies for 1 ​h at 4 ​°C, the proportion of positive cells can be analysed by an Epics-XL-MCL flow cytometer (Beckman Coulter). The results we obtained were calculated using the FACS and can be programmed (Becton Dickinson (BD) Biosciences).

Multidifferentiation of human TSPCs {#sec2.3}
-----------------------------------

The differentiation potential of human TSPCs towards osteocytes and adipocytes was made *in vitro* as reported previously \[[@bib17]\]. TSPCs (Passage 5) were plated in 12-well plate and used for multidifferentiation experiments when reaching confluence. For osteogenic differentiation, medium was changed to osteogenic medium, and cells continued to be cultured for a further 14 days. Osteogenic induction medium was LG-DMEM containing 10% FBS and 1% penicillin-streptomycin-neomycin (PSN) as well as 1 ​nM dexamethasone, 20 ​mM β-glycerolphosphate, and 50 ​mM ascorbic acid. After 14 days, the cells were fixed and stained with crystal violet followed by staining with 0.5% (w/v) alizarin red S (pH 4.1, Sigma[-]{.ul}Aldrich) for 30 ​min. For adipogenic differentiation, cells were cultured in adipogenic medium containing 10% FBS, 500 ​nM dexamethasone, 50 ​μM indomethacin, 0.5 ​mM isobutylmethylxanthine and 10 ​μg/ml insulin (Sigma[-]{.ul}Aldrich) or continued to be cultured in complete medium for another 14 days. The adipogenesis was measured by staining with 0.3% fresh oil red O (Sigma[-]{.ul}Aldrich) so that red lipid droplets of adipocytes after staining can be seen. The cell plates, both osteogenic and adipogenic induction, were scanned and imaged by microscope.

Human TSPCs differentiation towards fibrocartilage cells {#sec2.4}
--------------------------------------------------------

TSPCs at Passage 5 were plated at 1 ​× ​10^4^ ​cells/cm^2^ and cultured in complete medium until the cells reached confluence. Complete medium supplemented with 10 ​ng/ml of TGF-β3 and 50 ​ng/ml of bone morphogenetic protein-2 (BMP-2) (R&D systems), 10^−7^ ​M dexamethasone, 40 ​μg/ml proline, 100 ​μg/ml pyruvate, 50 ​μg ascorbate-2-phosphate (all from Sigma[-]{.ul}Aldrich), and 1:100 diluted insulin, transferrin, selenium (ITS) Universal Cell Culture Supplement Premix (Becton Dickson, Franklin Lakes, NJ) was used as differentiation medium. When TSPCs started to be induced by differentiation medium, cells were photographed at Day 4, 7, and 14 to follow changes of morphology. The supernatant of TSPCs was collected at Day 4, 7, and 14 to measure the concentration of collagen I and II by enzyme-linked immunosorbent assay (ELISA) kits (R&D systems). Cells were also harvested at Day 0, 7, and 14 for detecting gene expression by quantitative real-time reverse transcription polymerase chain reaction (q-PCR) or fixed at Day 21 for immunofluorescence staining.

Heterotopic fibrochondrogenesis of TSPCs *in vivo* {#sec2.5}
--------------------------------------------------

To examine the fibrochondrogenesis differentiation effect of human TPSCs *in vivo*, we chose collagen II sponge prepared in our earlier study \[[@bib20]\] as cell carriers, assuring that cells can be loaded and not leaked out under the dorsal surface of nude mice. TSPCs were labelled with PKH 67 (Sigma--Aldrich) to observe cell viability in collagen II sponge. Approximately 10^6^ TSPCs were seeded in collagen II sponge and cultured in induction medium with TGF-β3 and BMP-2 or complete medium for 14 days before being transplanted into the dorsal surface of 8- to 10-week-old female immunocompromised nude mice subcutaneously \[[@bib8]\]. Collagen II sponge without cells was also transplanted as a control. Transplants were harvested after 4 weeks and then fixed by neural formalin, decalcified, and embedded with wax. The sections would be stained with Safranin O/Fast Green or immunohistochemistry staining (IHC).

Quantitative real-time reverse transcription PCR {#sec2.6}
------------------------------------------------

q-PCR was performed in accordance with the manufacturer\'s' protocols. In brief, TSPCs with or without treatment were harvested for total RNA extraction using a kind of RNA extraction mini kit (Invitrogen, Carlsbad, CA). Three hundred nanograms ​of mRNA was reverse transcribed to complementary DNA (cDNA) using first stand cDNA synthesis kit (Invitrogen). The mRNA expression levels were measured by real-time PCR by the SYBR green master mix and primers used for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), alpha 1 type I collagen (Col1α1), Sox 9, alpha1 type II collagen (Col2α1), and tenascin C are shown in [Table 1](#tbl1){ref-type="table"}. PCR conditions were as follows: 95 ​°C for 10min and then 40 cycles of 95 ​°C for 10s, 60 ​°C for 30s, and 72 ​°C for 30s. The mRNA level of target genes was normalized to that of GAPDH gene. Relative mRNA expression was calculated with the 2^-△△CT^. At least three independent experiments were performed to calculate the standard deviation of 2^-△△CT^.Table 1Human primer sequences.Table 1Human primersSequencesCol1⍺1Forward5′-CAGCCGCTTCACCTACAGC-3′Reverse5′- TTTTGTATTCAATCACTGTCTTGCC-3′Col2⍺1Forward5′- GGCAATAGCAGGTTCACGTACA -3′Reverse5′- CGATAACAGTCTTGCCCCACTT -3′Tenascin CForward5′- TCTCTGCACATAGTGAAAAACAATACC -3′Reverse5′- TCAAGGCAGTGGTGTCTGTGA -3′Sox 9Forward5′- TACGACTGGACGCTGGTGCC -3′Reverse5′- CCGTTCTTCACCGACTTCCTCC -3′GAPDHForward5′- CGTAAAGACCTCTATGCCAACA -3′Reverse5′- CGGACTCATCGTACTCCTGCT -3′

Immunofluorescence staining {#sec2.7}
---------------------------

Immunofluorescence staining was performed as reported previously \[[@bib21]\]. First, 70% ethanol was used to fix TSPCs for 10 ​min ​at room temperature and then the fixed cells were incubated by 1 ​× ​PBS with 0.2% Triton-X100. Second, the cells were incubated in blocking solution with 1% bovine serum albumin and 5% goat serum, to block the unspecific binding of antibodies, and then incubated with primary antibody, also diluted in 5% goat serum/1% bone serum albumin (BSA)-PBS, for overnight at 4 ​°C. The primary antibodies used were rabbit polyclonal anticollagen I (Abcam, 1:200), mouse monoclonal anticollagen II (Abcam, 1:200), rabbit polyclonal anti-Sox 9 (Santa Cruz, 1:50) and mouse monoclonal antitenascin C (Abcam, 1:200). The blocking solution without any antibody was chosen as a negative control. Third, the cells were incubated in corresponding secondary antibodies that were also diluted in 5% goat serum/1% BSA--PBS in the dark for at least 1 ​h at room temperature. The secondary antibodies used were Alexa Fluor® 594 goat antirabbit (1:500) (red), Alexa Fluor@ 488 goat antimouse (green), 2 ​μg/ml (Invitrogen) (1:500). Finally, after several washes with 1 ​× ​PBS, the cell nuclei were counterstained with DAPI (5 ​μg/ml) (Invitrogen) for 1 ​min. The fluorescence was imaged using confocal microscopy (Leica Microsystems, Germany).

Immunohistochemistry staining {#sec2.8}
-----------------------------

Transplants harvested from nude mice were fixed by 4% neutral buffered formalin for 48 ​h and embedded with paraffin wax. We prepared at least 10 sections in 5 ​μm thickness using 1130/Biocut microtome (Reichert-Jung GmbH, Nussloch, Germany). These sections were stained with Safranin O/Fast Green \[[@bib20]\]. The expression of collagen I and II was detected by immunohistochemistry staining. The primary antibodies used were as same as those used in immunofluorescence staining, whereas the secondary antibodies used were horseradish peroxidase (HRP) goat-anti-rabbit (1:1000) or HRP goat-anti-mouse (1:1000) (all from Santa Cruz company). Sections that were only incubated with secondary antibodies were used as negative controls. Subsequently, the immunoreactivity was detected by the mouse and rabbit-specific 3,3\'-diaminobenzidine (DAB) detection IHC kit (Abcam).

Data analysis {#sec2.9}
-------------

All data were presented as mean ​± ​standard deviation, and all reported representative data were from at least three independent experiments. All statistical analyses were performed with student\'s t-test. *P\<*0.05 was considered as statistically significant.

Results {#sec3}
=======

Characterization and multidifferentiation potential of TSPCs isolated from human patellar tendon {#sec3.1}
------------------------------------------------------------------------------------------------

To examine the colony-forming potential of TSPCs, human tendon cells were isolated and cultured at different cell densities and the colonies formed were observed by crystal violet staining ([Figure 1](#fig1){ref-type="fig"}A). It appears that isolated TSPCs were able to form colonies at different cell density with an increasing trend of colony formation in a higher cell density. In addition, the morphology of TSPCs after being subcultured was observed to have the difference between cells at Passage 0 and those at Passage 1. Star-shaped cells were seen at Passage 0, whereas fibroblast-like cells were observed at Passage 1 ([Figure 1](#fig1){ref-type="fig"}B).Figure 1**Isolation and identification of human tendon-derived stem/progenitor cells (TSPCs)**. (A) The colony-forming ability of TSPCs at different cell density, scale bar 0.5 ​cm (B) Morphology of tendon cells, star shaped cells were observed at Passage 0 (left) although fibroblast-like cells were observed at Passage 1 (right), scale bar 100 ​μm (C) Flow cytometry analysis of the expression of cell surface markers of TSPCs at Passage 3, including MSCs markers (CD29，CD44 and CD105), monocytic and neutrophil marker (CD14), leucocyte marker (CD45) and fibroblastic marker (CD90) (D) Osteogenic potential of TSPCs at Passage 5 *in vitro* as visualized by calcium nodules (red) with alizarin red staining, scale bar 0.5 ​cm (left), scale bar 100 ​μm (middle); and quantitative measurement of the area of calcium nodules (E) Adipogenic potential of TSPCs at Passage 5 *in vitro* as detected by oil drops (red) with oil red staining, scale bar 0.5 ​cm (left), scale bar 100 ​μm (middle); and quantitative measurement of the area of oil drops. \*\*\*p ​\< ​0.001.Figure 1

Flow cytometric analysis was employed to examine if TSPCs express mesenchymal stem cell surface markers, CD29 and CD44. It was revealed that approximately 99.67% and 99.87% cells were positive for CD29 and CD44, respectively. They were mostly negative for CD45 (0.32%), a leucocyte marker, and only a small proportion of TSPCs was positive CD14 (12.12%), known as a monocytic and neutrophil marker ([Figure 1](#fig1){ref-type="fig"}C). In addition, CD 90 negative in BMSCs, was highly expressed in 99.11%.of cells. Interestingly, approximately, 84.75% of cells expressed CD105, a TGF-beta receptor accessory molecule ([Figure 1](#fig1){ref-type="fig"}C).

Isolated tendon cells were cultured in different condition media to examine their differentiation potential towards osteocytes and adipocytes. Red calcium nodules stained by alizarin red S were observed after 14-day osteogenic induction, which were not observed in the control group ([Figure 1](#fig1){ref-type="fig"}D). In addition, lipid droplets formation was detected in adipogenic induction medium after being induced for 14 days, which were not found in the control group ([Figure 1](#fig1){ref-type="fig"}E). These results indicated that TSPCs are stem cell--like cells with multidifferentiating potential.

Induction of fibrochondrogenic-like cells of TSPCs with TGF-β3 and BMP-2 *in vitro* {#sec3.2}
-----------------------------------------------------------------------------------

Then, we examined the differentiation potential of TSPCs to become fibrochondrocyte-like cells. As shown in [Figure 2](#fig2){ref-type="fig"}A, after being cultured in an induction medium with TGF-β3 and BMP-2 for 4 days, some TSPCs exhibited round shape, but those without induction showed fibroblastic cell morphology. At Day 7 after induction, some TSPCs in TGF-β3 and BMP-2 treated group formed round or irregularly shaped with flat colonies or aggregates, and at Day 14, these colonies/aggregates became more spherical shaped. By comparison, TSPCs cultured in noninduced medium displayed fibroblastic morphology at all time points ([Figure 2](#fig2){ref-type="fig"}A).Figure 2**Fibrochondrogenesis of human TSPCs at different time points**. (A) Cell morphology of TSPCs treated with or without TGF-β3 and BMP-2 was observed by microscopy at different time points, scale bar 100 ​μm (B) Expression levels of collagen I and II in the culture supernatant of TSPCs induced by TGF-β3 and BMP-2 at different time points were detected by ELISA kits, and culture supernatant of cells without TGF-β3 and BMP-2 was used as control group, \*p ​\< ​0.05 (C) mRNA levels of fibrocartilage-like cells, including fibroblastic marker (Col1α1), chondrogenic markers (Col2α1 and Sox 9), and bone--tendon junction marker (tenascin C) were examined by qRT-PCR at different time points, and cells cultured in complete medium before induction were referred as Day 0, \*\#p ​\< ​0.05. \*\*\#\#p ​\< ​0.01.Figure 2

To further determine the characteristics of TSPCs after induction, the level of collage I and II protein secreted by TSPCs was examined by ELISA ([Figure 2](#fig2){ref-type="fig"}B). Our results showed that the expression levels of both collage I and II in supernatant were higher in TGF-β3 and BMP-2 group than that in noninduced group ([Figure 2](#fig2){ref-type="fig"}B). In addition, collagen I and II secretion of TSPCs increased with time in TGF-β3 and BMP-2 group from Day 4 to Day 14, whereas no significant difference can be seen in noninduced group over the 14-day induction period ([Figure 2](#fig2){ref-type="fig"}B).

Later, we examined the mRNA expression of fibrocartilage-like cell marker genes. Total RNAs were extracted from TSPCs treated with TGF-β3 and BMP-2 at Day 0, 7, and 14 and subjected to q-PCR analyses. It was revealed that the relative expressions of fibroblastic gene (Col1α1), chondrocytes-related genes (Col2α1 and Sox 9) and bone--tendon junction marker gene (tenascin C) were all upregulated in TSPCs treated with TGF-β3 and BMP-2 at different time point ([Figure 2](#fig2){ref-type="fig"}C). Notably, fibroblastic marker, Col1α1, increased sharply at Day 7 when compared with Day 0 but had no significant increase between Day 7 and Day 14. Chondrocytes-related genes (Col2α1 and Sox 9) slightly increased at Day 7, followed by a sharp rise at Day 14 in comparison to Day 0. Tenascin C gene was slightly upregulated at Day 7 and then strongly upregulated at Day 14 compared with Day 0. The expression pattern of the fibroblastic gene and chondrogenic maker genes suggested that TSPCs can undergo fibrogenesis at an early time point (Day 7) and subsequently chondrogenesis at a late time point (Day 14), in the presence of TGF-β3 and BMP-2.

The expressions of collagen I, collagen II, Sox 9, and tenascin C were further confirmed using immunofluorescence staining. As shown in [Figure 3](#fig3){ref-type="fig"}A--B, collagen I was detected in all groups, and further induced in the presence of TGF-β3 and BMP-2. Collagen II and Sox 9 were detected only in TGF-β3 and BMP-2 treated group, but not be found in the noninduced group. Tenascin C expressions were higher in TGF-β3 and BMP-2 treated group, when compared with the noninduced group. Collectively, these data suggested human TSPCs expressed fibrochondrogenic markers in the presence of TGF-β3 and BMP-2, indicating that TSPCs has been differentiated into fibrocartilage-like cells *in vitro*.Figure 3**The protein expression of fibrocartilage-like cells by using immunofluorescence staining**. (A) Morphology of TSPCs was photographed by phase-contrast microscope, scale bar 100 ​μm (B) The protein expression of fibrocartilage-like cells was detected by immunofluorescence staining after TSPCs were cultured in chondrogenic medium with TGF-β3 and BMP-2 for 21 days. TSPCs cultured in completed medium without induction for 21 days were used as a control. Fibroblastic marker (collagen I, red), chondrogenic markers (collagen II, green and Sox 9, red), and bone--tendon junction marker (tenascin C, green) were shown, and all nuclear area were stained by DAPI (blue), scale bar 100 ​μm (C) Quantitative measurement of positive areas was analysed by Image ProPlus software, \*\*\*p ​\< ​0.001.Figure 3

Induction of fibrochondrogenic-like cells of TSPCs *in vivo* {#sec3.3}
------------------------------------------------------------

Finally, to examine the fibrochondrogenic potential of TSPCs *in vivo*, TSPCs were cultured in collagen II sponge. It is noted that collagen II sponge has appropriate pore structure suitable for cell growth, such as appropriate pore size (50--130 ​μm) with good porosity, as observed by bright field microscope ([Figure 4](#fig4){ref-type="fig"}A). The viability of TSPCs cultured in collagen II sponge for 14 days was evident by PKH67 dye, which was used to label TSPCs ([Figure 4](#fig4){ref-type="fig"}B). To determine the fibrochondrogenic potential of TSPCs *in vivo*, TSPCs were seeded in collagen II sponge and cultured in induction medium with TGF-β3 and BMP-2 or in complete medium for 2 weeks, which were then transplanted into the immunocompromised nude mice. Collagen II sponge alone without TSPCs was used as a control. After 4 weeks, proteoglycan (red), which was surrounded by undegraded collagen II (blue), was found to be higher in the TGF-β3-- and BMP-2--treated TSPC group than in the noninduced TSPC group, suggesting TSPCs have been induced towards chondrocytes lineage ([Figure 4](#fig4){ref-type="fig"}C). No cells were found in collagen II sponge group, which indicated that proteoglycan was produced from TPSCs seeded in the collagen II sponge. In addition, positive area of proteoglycan in the TGF-β3 and BMP-2 pretreated TSPCs group was greater than that in noninduced TSPCs group. To confirm if these cells exhibit characteristics of fibrocartilage-like cells, the expressions of collagen I and II by IHC staining was performed ([Figure 4](#fig4){ref-type="fig"}D). There was significantly more collagen I than collagen II in the TGF-β3 and BMP-2 pretreated TSPCs group ([Figure 4](#fig4){ref-type="fig"}D).Figure 4**Induction of fibrochondrogenic-like cells of TSPCs*****in vivo**.* (A) Morphology of Collagen II sponge (left), scale bar 2 ​cm. Pore structure of collagen II sponge was photographed by bright field microscope (right), scale bar 100 ​μm (B) PKH67 labelled TSPCs were viable in the collagen II sponge after being cultured for 14 days. TSPCs were labelled by PKH67 (green) (left), and collagen II sponge was imaged by phase-contrast microscope (middle). The merged image of TSPCs and collagen II sponge (right) was shown, scale bar 100 ​μm (C) Proteoglycan-rich extracellular matrices were examined by Safranin O/Fast Green staining in all groups after TSPCs transplanted into nude mice for 4 weeks. Proteoglycan (red) was surrounded by collagen II sponge (blue), scale bar 100 ​μm (top). Higher magnification of images showed that the expression of proteoglycan was mainly around cells, scale bar 50 ​μm (bottom); and proteoglycan positive area was analysed by Image ProPlus software, \*p ​\< ​0.05, \#\#\#p ​\< ​0.001 (D) IHC staining of TSPCs in collagen II sponge showed strong expression of collagen I and moderate expression of collagen II, scale bar 100 ​μm (top) and 50 ​μm (bottom). Collagen positive area was normalized to total cell nuclear area by Image ProPlus software to quantify the collagen expression levels, \*p ​\< ​0.05.Figure 4

Discussion/conclusion {#sec4}
=====================

Previous studies have reported the chondrogenic differentiation from different sources of stem cells \[[@bib8],[@bib17],[@bib22]\]. Little, however, was evident that tendon stem cells could be differentiated into fibrochondrocyte-like cells. In particular, owing to the unique location of fibrocartilage tissue at bone--tendon junction and the limitation of the small number of tendon stem cells, it remains elusive that tendon stem cells could be readily differentiated into fibrocartilage-like cells. In this study, we have successfully isolated and identified stem cells/progenitors from human patellar tendon. We showed that TSPCs could be induced toward fibroblastic and chondrogenic-like cells in the presence of TGF-β3 and BMP-2. We provided evidence that TSPCs are capable of differentiating into fibrochondrocyte-like cells *in vitro* and *in vivo.*

The successful isolation of TSPCs is important because it provides a new cell resource to study its potential in fibrocartilage regeneration of bone--tendon junctions. The coexpression of the fibroblast markers, such as collagen I and the chondrocytes markers, such as collagen II, have been used to identify fibrocartilage cells in bone--tendon junction \[[@bib23]\]. Nevertheless, it is still difficult to define these cells, partly because a combination of different cell types are present in fibrocartilage at bone--tendon junction \[[@bib1],[@bib24],[@bib25]\], and there is no specific markers that can be used to distinguish them.

There are many factors which would influence the chondrogenic differentiation of stem cells, such as cell density, growth factors, and culture conditions \[[@bib26],[@bib27]\]. Rui et al. \[[@bib29]\] found that TGF-β3 could induce more proteoglycan and collagen II than TGF-β1, and BMP-2 could enhance the chondrogenic effect of TGF-β3 on synovium-derived stem cells *in vitro* \[[@bib28]\]. BMP alone has been shown to inhibit tendon formation during development, whereas TGF-β alone would inhibit mRNA expression of Col1α1 in chondrogenic induction of BMSCs \[[@bib30], [@bib31], [@bib32]\]. Our results showed that TSPCs express fibroblastic marker (collagen I) and chondrogenic markers (Sox 9 and collagen II) when cultured in the presence of TGF-β3 and BMP-2 ([Figure 2](#fig2){ref-type="fig"}), indicating that TSPCs were induced to fibrocartilage cells which are able to express two kinds of markers simultaneously or at least a mixture of fibroblasts and chondrocytes. This is in line with a previous study showing that fibrocartilage cells were likely to contain a mixture of fibroblasts and chondrocytes that express both collagen I and II \[[@bib9]\]. However, whether or not these cells contain the tenogenic phenotype remained to be further investigated.

The repair of bone--tendon junctions after injury is a slow process. Growth factors or mechanical stimuli are often used to stimulate the regeneration of fibrocartilage zone \[[@bib23],[@bib33], [@bib34], [@bib35]\]. In this study, we found that abundant proteoglycan was detected in TSPCs seeded in collagen II sponge after being transplanted into mice, indicating that the presence of fibrocartilage-like cells. These cells also expressed collagen I and certain levels of collagen II. Taken together, in this study, TSPCs were isolated and are able to be differentiated into fibrocartilage-like cells, which might serve as a potential cell source for the treatment of TSPC-based bone--tendon junction repair.
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